Richard S. Finn, MD, on Hepatocellular Carcinoma: Recent Data on Lenvatinib Plus Pembrolizumab

ESMO Congress 2022


Richard S. Finn, MD, of the Geffen School of Medicine at the University of California, Los Angeles, discusses primary phase III results from the LEAP-002 study of pembrolizumab, an anti–PD-1 therapy, plus lenvatinib, the orally available multiple receptor tyrosine kinase inhibitor, vs lenvatinib monotherapy in patients with advanced hepatocellular carcinoma (Abstract LBA34).


Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The LEAP-002 study was a large phase three double blind placebo controlled study in advanced liver cancer in the frontline setting, evaluating the combination of Lenvatinib and Pembrolizumab versus Lenvatinib alone. This study was based on earlier data, a single arm phase one B study in the frontline setting with both these drugs, which showed very interesting activity. A 36% objective response rate, as well as a survival of over 21 months, which in the first line setting of liver cancer was a signal to pursue this definitive study. Lenvatinib has already approved in the front line setting in the United States and Pembrolizumab has accelerated approval in the second line setting. So in this study, we demonstrated that the overall survival with the combination was over 21 months, which was expected. However, the control arm performed much better than we expected. That is to say Lenvatinib had a survival of about 19 months in this population. If we look at historical data with Lenvatinib, from the REFLECT study, the pivotal study that got it approved, overall survival was about 13 and a half months. So unfortunately, the study did not meet its primary endpoint of overall survival. There was a dual primary endpoint of PFS, and again, at the primary analysis for PFS, there was no significant difference between the two arms. We did see that with longer follow up that there was a tail to the curve for Len Pembro, looking at the two year benchmark about 16% of patients did not progress with a combination, whereas 9% on single agent Lenvatinib did not progress. When we look at objective responses, the objective response rate with the combination was 25% in line with what we saw in the phase one B and Lenvatinib had a response rate of about 17 and half percent, which was in line with what was expected with single agent Lenvatinib. When we look at safety, there were really no new safety signals. The safety profile looked like single agent Lenvatinib, no added toxicity with Pembrolizumab, but at the end of the day, the study did not meet its end point. We did establish that the combination does prolong a long survival in advanced liver cancer and specifically Lenvatinib as a single agent in advanced liver cancer provided a survival of 19 months, which is really a reminder that this drug plays an important role in our patients with advanced liver cancer, even in this modern age of new combinations that are being evaluated and being approved.

Related Videos

Colorectal Cancer

Marinde J.G. Bond, PhD Candidate, on Colorectal Liver Metastases: FOLFOX/FOLFIRI, Bevacizumab, and Panitumumab

Marinde J.G. Bond, PhD Candidate, of the University Medical Center, Utrecht, discusses phase III findings from the CAIRO5 study of the Dutch Colorectal Cancer Group, the first such trial in defined subgroups of patients with initially unresectable colorectal cancer liver metastases and left-sided and RAS/BRAF V600E wild-type tumor. The study compared FOLFOX/FOLFIRI plus either bevacizumab or panitumumab (Abstract LBA21).


Gynecologic Cancers

Paul A. DiSilvestro, MD, on Ovarian Cancer: New Data on Olaparib in Newly Diagnosed Disease

Paul A. DiSilvestro, MD, of Women & Infants Hospital and the Warren Alpert Medical School of Brown University, discusses overall survival results after a 7-year follow-up of the SOLO1/GOG-3004 trial for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation who received maintenance olaparib. Dr. DiSilvestro details the increasing role of such PARP inhibitors in ovarian cancer treatment and their benefit to patients (Abstract 517O).

Head and Neck Cancer

Jean-Pascal Machiels, MD, PhD, on Head and Neck Cancer: Recent Data on Pembrolizumab and Chemoradiation Therapy

Jean-Pascal Machiels, MD, PhD, of Belgium’s Cliniques universitaires Saint-Luc (UCLouvain), discusses the primary results of the phase III KEYNOTE-412 study of pembrolizumab plus chemoradiation therapy (CRT) vs placebo plus CRT for patients with locally advanced head and neck squamous cell carcinoma (Abstract LBA5).

Solid Tumors

Bernd Kasper, MD, PhD, on Desmoid Tumors: Results on Nirogacestat vs Placebo

Bernd Kasper, MD, PhD, of Germany’s Mannheim Cancer Center, discusses phase III data from the DeFi trial, the largest study conducted to date for patients with desmoid tumors. The trial showed that the gamma secretase inhibitor nirogacestat demonstrated improvements in all primary and secondary efficacy endpoints. Although considered benign because of their inability to metastasize, desmoid tumors can cause significant morbidity and, occasionally, mortality in patients (Abstract LBA2).

Kidney Cancer

Nizar M. Tannir, MD, on RCC: Data on Bempegaldesleukin Plus Nivolumab vs Tyrosine Kinase Inhibitors in Untreated Disease

Nizar M. Tannir, MD, of The University of Texas MD Anderson Cancer Center, discusses phase III findings from the PIVOT-09 study, which compared bempegaldesleukin plus nivolumab with the investigator’s choice of a tyrosine kinase inhibitor (either sunitinib or cabozantinib) in patients with previously untreated advanced renal cell carcinoma (Abstract LBA68).